In addition, it has been reported that TMB is not an accurate predictive biomarker for ICIs, for example, non-small cell lung cancer patients with KRAS and SKT11 co-mutations and high TMB do not respond to immunotherapy 51. Here, KRAS is linked to non-small cell lung carcinoma.